Last update April 17, 2016

Sodium Picosulfate

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Stimulant of the intestine and laxative drug through irritation of mucosa which is similar to bisacodyl.

Its low oral bioavailability with minimal intestinal absorption causes plasma levels to be very low, that explains the observed failure of excretion into breast milk (undetectable levels).
Authorized for use in infants from age one month old.

To prevent or treat constipation is essential to have a balanced and fiber-rich diet, with a lot of fluids and exercise.

Alternatives

  • Docusate ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Lactulose ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Liquid Paraffin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Sodium Picosulfate in other languages or writings:

Group

Sodium Picosulfate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Sodium Picosulfate in its composition:

List of 42 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 5 %
Molecular weight 499 daltons
Tmax 14 hours

References

  1. Gharehbaghi K, Gharehbaghi DR, Wierrani F, Sliutz G. [Treatment of Chronic Functional Constipation during Pregnancy and Lactation]. Z Geburtshilfe Neonatol. 2016 Abstract
  2. Müller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Abstract
  3. Friedrich C, Richter E, Trommeshauser D, de Kruif S, van Iersel T, Mandel K, Gessner U. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet. 2011 Abstract Full text (link to original source) Full text (in our servers)

Total visits

44,948

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM